Description of Conduct

GEMPASS Australia Limited (GEMPASS Australia), formerly GAMSAT Consortium Limited, seeks the revocation of authorisations A91441, A91442, A91443 (as varied by AA55019) and substitution of a new authorisation AA1000672.

GEMPASS Australia is seeking authorisation to give effect to and abide by the arrangement set out in its policies that govern the application for admission and the interviewing of applicants for admission to study medicine at graduate-entry medical schools that are members of GEMPASS Australia. GEMPASS Australia currently has 9 university members, being The University of Wollongong, Deakin University, The University of Western Australia, Griffith University, The University of Notre Dame Australia, The Australian National University, The University of Queensland, The University of Melbourne and Macquarie University.

The policies for which authorisation is sought for are the ‘Interview Policy’ and ‘Preference Policy’. Under the policies, graduate-entry medical school applicants submit a single online application to the Graduate Entry Medical Schools Admission System, listing up to a maximum of 6 medical schools in preferential order, and applicants will receive no more than one offer for an interview.

GEMPASS Australia seeks authorisation for a further 10 years.

The ACCC invites the views of interested parties on this application. Submissions are requested by 19 June 2024. If you wish to make a submission in relation to this matter, please lodge it via this web form.

An indicative timeline for the ACCC’s assessment is set out below.

Indicative date

Stage in assessment process

10 May 2024

Lodgement of application and supporting submission.

June 2024

Public consultation process begins.

19 June 2024

Closing date for submissions from interested parties.

July 2024

Applicant responds to issues raised in the public consultation process.

August 2024

Draft determination.

August/September 2024

Public consultation on draft determination including any conference if called.

November 2024

Final determination.



Authorisation number(s)

  • AA1000672-1